...
search icon
arwr-img

Arrowhead Pharmaceuticals Inc, Common Stock

ARWR

NSQ

$67.875

+$1.41

(2.12%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$9.03B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
496.69K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.29
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.57 L
$72.36 H
$67.875

About Arrowhead Pharmaceuticals Inc, Common Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Pasadena, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameARWRSectorS&P500
1-Week Return-6.14%0.21%-1.85%
1-Month Return64.25%0.87%2.47%
3-Month Return110.95%11.96%2.15%
6-Month Return325.54%15.51%13.25%
1-Year Return226.47%12.08%15.37%
3-Year Return113.94%14.46%77.31%
5-Year Return-17.08%36.2%82.6%
10-Year Return1011.54%118.34%237.32%

Financials

Sep '21Sep '22Sep '23Sep '24Sep '255YR TREND
Total Revenue138.29M243.23M240.74M3.55M829.45M[{"date":"2021-09-30","value":16.67,"profit":true},{"date":"2022-09-30","value":29.32,"profit":true},{"date":"2023-09-30","value":29.02,"profit":true},{"date":"2024-09-30","value":0.43,"profit":true},{"date":"2025-09-30","value":100,"profit":true}]
Cost of Revenue-10.42M12.49M18.59M-[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":56.04,"profit":true},{"date":"2023-09-30","value":67.18,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":"-","profit":true}]
Gross Profit138.29M243.23M240.74M3.55M-[{"date":"2021-09-30","value":56.85,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":98.97,"profit":true},{"date":"2024-09-30","value":1.46,"profit":true},{"date":"2025-09-30","value":"-","profit":true}]
Gross Margin100.00%100.00%100.00%100.00%-[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":100,"profit":true},{"date":"2025-09-30","value":"-","profit":true}]
Operating Expenses287.32M421.74M445.74M604.63M731.10M[{"date":"2021-09-30","value":39.3,"profit":true},{"date":"2022-09-30","value":57.69,"profit":true},{"date":"2023-09-30","value":60.97,"profit":true},{"date":"2024-09-30","value":82.7,"profit":true},{"date":"2025-09-30","value":100,"profit":true}]
Operating Income(149.04M)(178.51M)(205.00M)(601.08M)98.35M[{"date":"2021-09-30","value":-151.54,"profit":false},{"date":"2022-09-30","value":-181.51,"profit":false},{"date":"2023-09-30","value":-208.45,"profit":false},{"date":"2024-09-30","value":-611.19,"profit":false},{"date":"2025-09-30","value":100,"profit":true}]
Total Non-Operating Income/Expense14.31M10.83M(4.52M)(21.01M)(46.81M)[{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":75.69,"profit":true},{"date":"2023-09-30","value":-31.56,"profit":false},{"date":"2024-09-30","value":-146.83,"profit":false},{"date":"2025-09-30","value":-327.13,"profit":false}]
Pre-Tax Income(140.85M)(172.71M)(206.49M)(612.46M)19.79M[{"date":"2021-09-30","value":-711.77,"profit":false},{"date":"2022-09-30","value":-872.8,"profit":false},{"date":"2023-09-30","value":-1043.52,"profit":false},{"date":"2024-09-30","value":-3095.11,"profit":false},{"date":"2025-09-30","value":100,"profit":true}]
Income Taxes2.00K3.79M2.78M(2.77M)21.42M[{"date":"2021-09-30","value":0.01,"profit":true},{"date":"2022-09-30","value":17.67,"profit":true},{"date":"2023-09-30","value":13,"profit":true},{"date":"2024-09-30","value":-12.92,"profit":false},{"date":"2025-09-30","value":100,"profit":true}]
Income After Taxes(140.85M)(176.49M)(209.28M)(609.69M)(1.63M)[{"date":"2021-09-30","value":-14084800000,"profit":false},{"date":"2022-09-30","value":-17649400000,"profit":false},{"date":"2023-09-30","value":-20927500000,"profit":false},{"date":"2024-09-30","value":-60969300000,"profit":false},{"date":"2025-09-30","value":-163100000,"profit":false}]
Income From Continuous Operations(140.85M)(172.71M)(209.28M)(609.69M)30.11M[{"date":"2021-09-30","value":-467.72,"profit":false},{"date":"2022-09-30","value":-573.52,"profit":false},{"date":"2023-09-30","value":-694.94,"profit":false},{"date":"2024-09-30","value":-2024.62,"profit":false},{"date":"2025-09-30","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}]
Net Income(140.85M)(176.49M)(205.28M)(599.49M)(1.63M)[{"date":"2021-09-30","value":-14084800000,"profit":false},{"date":"2022-09-30","value":-17649400000,"profit":false},{"date":"2023-09-30","value":-20527500000,"profit":false},{"date":"2024-09-30","value":-59949300000,"profit":false},{"date":"2025-09-30","value":-163100000,"profit":false}]
EPS (Diluted)(1.36)(1.68)(1.92)(5.01)(0.01)[{"date":"2021-09-30","value":-136,"profit":false},{"date":"2022-09-30","value":-168,"profit":false},{"date":"2023-09-30","value":-192,"profit":false},{"date":"2024-09-30","value":-501,"profit":false},{"date":"2025-09-30","value":-1,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ARWR
Current Ratio 4.86

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ARWR
ROA (LTM) 4.87%
ROE (LTM) 8.67%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ARWR
Debt Ratio Lower is generally better. Negative is bad. 0.64
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ARWR
Trailing PE NM
Forward PE 111.11
P/S (TTM) 10.80
P/B 18.84
Price/FCF 689
EV/R 9.92
EV/Ebitda 49.92
PEG NM

FAQs

What is Arrowhead Pharmaceuticals Inc share price today?

Arrowhead Pharmaceuticals Inc (ARWR) share price today is $67.875

Can Indians buy Arrowhead Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Arrowhead Pharmaceuticals Inc (ARWR) on Vested. To buy Arrowhead Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARWR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arrowhead Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Arrowhead Pharmaceuticals Inc (ARWR) via the Vested app. You can start investing in Arrowhead Pharmaceuticals Inc (ARWR) with a minimum investment of $1.

How to invest in Arrowhead Pharmaceuticals Inc shares from India?

You can invest in shares of Arrowhead Pharmaceuticals Inc (ARWR) via Vested in three simple steps:

  • Click on Sign Up or Invest in ARWR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arrowhead Pharmaceuticals Inc shares
What is Arrowhead Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Arrowhead Pharmaceuticals Inc (ARWR) is $72.36. The 52-week low price of Arrowhead Pharmaceuticals Inc (ARWR) is $9.57.

What is Arrowhead Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arrowhead Pharmaceuticals Inc (ARWR) is 18.84

What is the Market Cap of Arrowhead Pharmaceuticals Inc?

The market capitalization of Arrowhead Pharmaceuticals Inc (ARWR) is $9.03B

What is Arrowhead Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Arrowhead Pharmaceuticals Inc is ARWR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top